Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan T Remaley

Showing results (21-30 of 469) with videos related to

Pageof 47
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|May 2, 2023
Can "Bad" HDL Be Turned Good Again?Amaury Dasseux, Alan T Remaley
Current Opinion in Endocrinology, Diabetes, and Obesity|February 13, 2010
MicroRNAs in atherosclerosis and lipoprotein metabolismKasey C Vickers, Alan T Remaley
Journal of Lipid Research|March 22, 2013
HDL and cholesterol: life after the divorce?Kasey C Vickers, Alan T Remaley
Expert Opinion on Medical Diagnostics|March 19, 2013
High-density lipoprotein: what is the best way to measure its antiatherogenic potential?Alan T Remaley, G Russell Warnick
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2013
Measurement of lecithin-cholesterol acyltransferase activity with the use of a Peptide-proteoliposome substrateBoris L Vaisman, Alan T Remaley
Journal of Laboratory and Precision Medicine|May 5, 2020
GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk AssessmentRami A Ballout, Alan T Remaley
Current Opinion in Lipidology|November 5, 2013
Reconstituted HDL for the acute treatment of acute coronary syndromeBrian R Krause, Alan T Remaley
Current Opinion in Lipidology|March 16, 2012
Lipid-based carriers of microRNAs and intercellular communicationKasey C Vickers, Alan T Remaley
Atherosclerosis|February 8, 2020
Methodological issues regarding: "A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals"Alan T Remaley, James D Otvos
Atherosclerosis|March 1, 2017
High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosisScott M Gordon, Alan T Remaley
Pageof 47

Showing results (21-30 of 469) with videos related to

Sort By:
Pageof 47
Arteriosclerosis, Thrombosis, and Vascular Biology|May 2, 2023
Can "Bad" HDL Be Turned Good Again?Amaury Dasseux, Alan T Remaley
Current Opinion in Endocrinology, Diabetes, and Obesity|February 13, 2010
MicroRNAs in atherosclerosis and lipoprotein metabolismKasey C Vickers, Alan T Remaley
Journal of Lipid Research|March 22, 2013
HDL and cholesterol: life after the divorce?Kasey C Vickers, Alan T Remaley
Expert Opinion on Medical Diagnostics|March 19, 2013
High-density lipoprotein: what is the best way to measure its antiatherogenic potential?Alan T Remaley, G Russell Warnick
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2013
Measurement of lecithin-cholesterol acyltransferase activity with the use of a Peptide-proteoliposome substrateBoris L Vaisman, Alan T Remaley
Journal of Laboratory and Precision Medicine|May 5, 2020
GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk AssessmentRami A Ballout, Alan T Remaley
Current Opinion in Lipidology|November 5, 2013
Reconstituted HDL for the acute treatment of acute coronary syndromeBrian R Krause, Alan T Remaley
Current Opinion in Lipidology|March 16, 2012
Lipid-based carriers of microRNAs and intercellular communicationKasey C Vickers, Alan T Remaley
Atherosclerosis|February 8, 2020
Methodological issues regarding: "A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals"Alan T Remaley, James D Otvos
Atherosclerosis|March 1, 2017
High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosisScott M Gordon, Alan T Remaley
Pageof 47